ESR1 and breast cancer: The COX-2 inhibitor celecoxib has been shown to inhibit in vitro growth of MDA-MB-231 breast cancer cell and this cell line is estrogen receptor negative suggesting that celecoxib maybe a potential agent for the prevention of ER negative tumours.